Combination products for treating cancer

Abstract

The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.

1 . A method for treating cancer comprising the simultaneous, separate, or sequential administration of:
 (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) comprising the sequence SEQ ID NO:1, or an ortholog or derivative thereof,   (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) comprising the sequence SEQ ID NO:2, or an ortholog or derivative thereof,   (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) comprising the sequence SEQ ID NO:3, or an ortholog or derivative thereof, and   (iv) gemcitabine,   to a patient in need thereof.   
     
     
         2 . The method of  claim 1 , for the inhibition of tumor metastazing. 
     
     
         3 . The method of  claim 1 , for treating pancreatic cancer. 
     
     
         4 . The method of  claim 1 , for treating hepatocellular carcinoma. 
     
     
         5 . The method of  claim 1 , wherein said patient is a human. 
     
     
         6 . The method of  claim 1 , comprising the administration of at least one nucleic acid sequence coding simultaneously for the human deoxycytidine kinase protein (dck) comprising the sequence SEQ ID NO:2, or an ortholog or derivative thereof, and for the human uridine monophosphate kinase protein (umk) comprising the sequence SEQ ID NO:3, or an ortholog or derivative thereof. 
     
     
         7 . The method of  claim 6 , comprising the administration of at least one nucleic acid sequence coding for a polypeptide comprising the two proteins  Homo sapiens  deoxycytidine kinase protein (dck) and  Homo sapiens  uridine monophosphate kinase protein (umk) linked by the cleavable Foot-and-Mouth-Disease virus (FMDV) 2A peptide, which polypeptide comprises the sequence SEQ ID NO: 10. 
     
     
         8 . The method of  claim 1 , wherein said nucleic acid sequences are comprised within at least one vector. 
     
     
         9 . The method of  claim 8 , wherein said plasmid vector comprises the sequence SEQ ID NO:11, and comprises nucleic acid sequences coding for the  Homo sapiens  somatostatin 2 receptor protein and for a polypeptide comprising the two proteins  Homo sapiens  deoxycytidine kinase protein (dck) and  Homo sapiens  uridine monophosphate kinase protein (umk) linked by the cleavable Foot-and-Mouth-Disease virus (FMDV) 2A peptide. 
     
     
         10 . The method of  claim 8 , wherein said plasmid(s) vector(s) is associated with non-lipid cationic polymers. 
     
     
         11 . A pharmaceutical composition comprising:
 (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (SST2) comprising the sequence SEQ ID NO: 1, or an ortholog or derivative thereof,   (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (DCK) comprising the sequence SEQ ID NO: 2, or an ortholog or derivative thereof, and   (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (UMK) comprising the sequence SEQ ID NO: 3, or an ortholog or derivative thereof.   
     
     
         12 . The pharmaceutical composition according  claim 11 , wherein said nucleic acid sequences are comprised within a plasmid vector comprising the sequence SEQ ID NO:11, and comprising nucleic acid sequences coding for the  Homo sapiens  somatostatin 2 receptor protein and for a polypeptide comprising the two proteins  Homo sapiens  deoxycytidine kinase protein (dck) and  Homo sapiens  uridine monophosphate kinase protein (umk) linked by the cleavable Foot-and-Mouth-Disease virus (FMDV) 2A peptide. 
     
     
         13 . The pharmaceutical composition according  claim 12 , wherein said plasmid vector is associated with polyethylenimine (PEI). 
     
     
         14 . A plasmid vector comprising the sequence SEQ ID NO:11, and comprising nucleic acid sequences coding for the  Homo sapiens  somatostatin 2 receptor protein and for a polypeptide comprising the two proteins  Homo sapiens  deoxycytidine kinase protein (dck) and  Homo sapiens  uridine monophosphate kinase protein (umk) linked by the cleavable Foot-and-Mouth-Disease virus (FMDV) 2A peptide. 
     
     
         15 . The method according to  claim 3 , wherein said gemcitabine is administrated at a dose of equal or less than 750 mg/m 2  per day. 
     
     
         16 . The method of  claim 8 , wherein said vector is a plasmid vector. 
     
     
         17 . The method of  claim 10 , wherein the non-lipid cationic polymers are polyethylenimine (PEI).